Terminated PHASE2 INTERVENTIONAL 4-arm NCT03289143

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease

Sponsor: Genentech, Inc.

Conditions Alzheimer's Disease

Interventions Placebo Semorinemab [18F]GTP1

Updated 35 times since 2017 Last updated: Feb 16, 2022 Started: Oct 4, 2017 Primary completion: Jan 15, 2021 Completion: Jan 15, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Study was terminated during Open Label Extension period because analyses of placebo-controlled Blinded portion of study did not show any evidence of clinical efficacy or modulation of accumulation of tau PET signal at any of the doses studied.

Other terminated trials from Genentech, Inc.

More terminations from Genentech, Inc.

Other Alzheimer's Disease trials with similar outcome

Browse all Alzheimer's Disease trials

This PHASE2 trial investigates Alzheimer's Disease and is currently terminated or withdrawn. Genentech, Inc. leads this study, which shows 35 recorded versions since 2017 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

35 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Apr 2022 — Jul 2024 [monthly]

Terminated PHASE2

Status: Completed → Terminated
Jun 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 30 earlier versions

Apr 2021 — Jun 2021 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Jan 2021 — Apr 2021 [monthly]

Active Not Recruiting PHASE2
Oct 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE2
Sep 2020 — Oct 2020 [monthly]

Active Not Recruiting PHASE2
Jul 2020 — Sep 2020 [monthly]

Active Not Recruiting PHASE2
Apr 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE2
Feb 2020 — Apr 2020 [monthly]

Active Not Recruiting PHASE2
Dec 2019 — Feb 2020 [monthly]

Active Not Recruiting PHASE2
Nov 2019 — Dec 2019 [monthly]

Active Not Recruiting PHASE2
Aug 2019 — Nov 2019 [monthly]

Active Not Recruiting PHASE2
May 2019 — Aug 2019 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Apr 2019 — May 2019 [monthly]

Recruiting PHASE2
Mar 2019 — Apr 2019 [monthly]

Recruiting PHASE2
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE2
Jan 2019 — Feb 2019 [monthly]

Recruiting PHASE2
Dec 2018 — Jan 2019 [monthly]

Recruiting PHASE2
Nov 2018 — Dec 2018 [monthly]

Recruiting PHASE2
Oct 2018 — Nov 2018 [monthly]

Recruiting PHASE2
Sep 2018 — Oct 2018 [monthly]

Recruiting PHASE2
Aug 2018 — Sep 2018 [monthly]

Recruiting PHASE2
Jul 2018 — Aug 2018 [monthly]

Recruiting PHASE2
Jun 2018 — Jul 2018 [monthly]

Recruiting PHASE2
May 2018 — Jun 2018 [monthly]

Recruiting PHASE2
Apr 2018 — May 2018 [monthly]

Recruiting PHASE2
Mar 2018 — Apr 2018 [monthly]

Recruiting PHASE2
Feb 2018 — Mar 2018 [monthly]

Recruiting PHASE2
Jan 2018 — Feb 2018 [monthly]

Recruiting PHASE2
Dec 2017 — Jan 2018 [monthly]

Recruiting PHASE2
Nov 2017 — Dec 2017 [monthly]

Recruiting PHASE2
Oct 2017 — Nov 2017 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.

Data source: Genentech, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

's-Hertogenbosch, Netherlands , Aalborg, Denmark , Abington, United States , Albacete, Spain , Albany, United States , Amsterdam, Netherlands , Atlanta, United States , Atlantis, United States , Bangor, United States , Barakaldo, Spain and 106 more locations